Reported 6 months ago
The article discusses how AstraZeneca has unveiled a more ambitious strategic plan compared to Pfizer, aiming to increase its revenue to $80 billion by 2030 by launching at least 20 new medicines. AstraZeneca plans to focus on cancer drugs, rare-disease therapies, and biologics, while Pfizer aims to grow revenue to $103.5 billion by 2030 with a focus on cancer medicines as well. AstraZeneca's approach emphasizes executing on its existing pipeline without extensive business development work, potentially leading to better stock performance in the coming years compared to Pfizer, which may need to address debt incurred from acquisitions.
Source: YAHOO